Those patients with perianal Crohn's disease or ul cerative colitis experience a difficult to treat disease process with a delayed state and often inability to heal despite current therapies. The approaches currently used to treat these patients with corticosteroids, antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, and surgical repair are limited in their healing ability. This review presents all current literature since emergence in the early 2000s of stem cell therapy for patients with perianal inflammatory bowel disease and analyzes the efficacy, outcomes and safety within these studies.
INTRODUCTION
Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract that can disturb anywhere from the mouth to the anus. One of the most common manifestations of CD includes perianal disease, specifical ly including fistulas, abscesses, fissures, and stenosis. These complications frequently result in a significant burden for the patient due to abscess formation, perianal leakage, pain, and an overall decreased quality of life. Treatment options for perianal CD have traditionally included symptomatic management, antibiotics, and medications including immunomodulators and anti tumor necrosis factor α agents, or surgery in cases with persistent refractory disease. However, surgical options are often limited and come with their own risks, which include incontinence and recurrence of disease. Recently, however, mesenchymal stem cells (MSCs) have been studied in perianal CD and results have been quite promising. This paper provides an uptodate review on the use of MSC for perianal CD.
MSC therapy has been demonstrated to be a potentially effective treatment for perianal CD in a variety of ways. These stem cells are nonhematopoietic multipotent cells that can depress immune activation and encourage healing of inflamed tissue. MSCs have been found to hinder dendritic cell formation from monocytes, restrict naïve and memory CD4+ cells, stop T cell activation via inhibitory effects on mature dendritic cells, and encourage proliferation of regulatory T cells [16] . In addition, MSCs can travel to the site of inflammation and there contribute to local healing [7] . Over the last several years, multiple studies have evaluated au tologous and allogeneic MSCs, to determine the safety and efficacy of treating perianal CD. The results are promising demonstrating significantly increased rates of healing for perianal disease refractory to conventional therapy alone. Here we will present studies involving autologous adipose, then autologous bone marrow studies, and then allogeneic adipose and bone marrow studies.
AUTOLOGOUS ADIPOSE STEM CELL STUDIES
The first report describing MSCs for perianal CD was a case report by GarcíaOlmo et al [8] in 2003. Here, a rectovaginal fistula in CD was successfully healed seven days after the injection of adiposederived MSCs. This same author then executed a phase Ⅰ clinical trial involving four individuals suffering from refractory com plex Crohn's fistulas, again injecting the fistula tracts with autologous adiposederived MSCs. Tissue repair was reported in three of four of patients at eight weeks, without adverse events during the one and two year follow up visits [9] . GarcíaOlmo et al [10] then led a third study, a phase IIb trial, involving 49 patients with complex perianal cryptoglandular and CD fistulas comparing fibrin glue therapy to fibrin glue plus adiposederived MSCs. Individuals in this latter group received a second dose of MSC if fistula healing did not appear after two months. In those with CD, fistula healing at twelve months occurred in five of seven (71%) in those given fibrin glue plus MSC as opposed to one of seven (14%) in those given fibrin glue alone [10] . Quality of life was also found to be better in the combined treatment group [10] . These early positive findings for MSCs treating perianal CD laid the groundwork for further work. In a doseescalation phase Ⅰ trial led by Cho et al [11] , ten individuals affected by perianal CD fistulas were given autologous adipose derived MSCs. Following two months of treatment, fistula healing marked by epithelization was detected in three in ten (30%), with continued results at the eight month visit.
Lee et al [12] performed a followup phase Ⅱ study, including 33 treated subjects given injections of fibrin glue and adiposederived MSCs with doses proportionate to fistula sizes, followed by repeat injections of increased doses if fistula closure did not complete by two months. Fistula healing was found in twentyseven of thirty three (82%) individuals by two months, with continued healing to twelve months in twentythree of twentysix (88%) [12] . The other six subjects of the original group developed an incomplete closure, five of which had a > 50% closure and decreased drainage [12] . Cho et al [13] did a further follow up study from their 2013 phase Ⅰ trial. Here adiposederived MSC in fistulizing CD analyzed fortyone of fortythree patients for 12 mo and 24 mo weeks showing complete healing in 80.8% (21 of 26) patients in the complete healing pool and 75% (27 of 36) patients in the modified intention to treat pool [13] . The modified intention to treat pool included those patients who had efficacy data at one year in the phase Ⅱ study. Interestingly, regarding maintenance of complete closure, 27 patients achieved this at eight weeks, twentythree of 26 (88.5%) at twelve months, twenty of 24 (83.3%) at twentyfour months [13] . Recurrence was seen in 11.5% at one year and 16.7% at two years. For the modified intention to treat group nine patients (25%) demonstrated an incomplete response at two years. Thus, the authors concluded that the use of MSC is safe and efficacious in perianal fistulizing disease.
For the Cho et al [13] study, one of the most unique aspects is the analysis of patients with MSC therapy and antiTNF therapy. Of the twentyfour month group of twentyseven patients showing complete healing, four patients receiving infliximab were documented. This was used due to enteric CD exacerbation, with 75% of these patients having complete closure prior to treatment with infliximab and having continued resolution of their fistula after infusion. More recently, Dietz et al [14] led a phase Ⅰ clinical trial over a six month period assessing the safety and feasibility of autologous stem cell therapy for persistent, Dailey FE et al . Stem cell therapy for perianal CD 6 wk, with a maximum of 2 internal and 3 external openings. The patients were kept on concurrent therapy during this study with biologics or immunomodulators or antibiotics. Twentyfour weeks after one local injection, those given MSC had significant clinical improvement delineated by closure of the external fistula tract and no fluid collections > 2 cm on magnetic resonance imaging (MRI). The authors found 53 of 107 subjects (50%) treated with MSC healed as opposed to 36 of 105 subjects (34%) given placebo (n = 36). Additionally, those given MSC experienced a much shorter time to remission of their disease: 6.7 wk as opposed to 14.6 wk. Explanations for why those in the placebo group experienced such high rates of fistula closure and remission include the fact that all patients received fistula curettage, internal orifice closure, and surgical drainage. While this study did not address the potential benefits of repeat injections of MSCs or dosage of injections based on size of fistula tract, it did provide largescale, sustained positive results of MSCs for perianal CD. An expansion of this project has been developed in the United States, which is also a phase Ⅲ multicenter, randomized clinical trial evaluating allogeneic adiposederived MSC for perianal CD [16] .
ALLOGENEIC BONE MARROW STEM CELL STUDIES
Finally, Molendijk et al [17] studied allogeneic MSCs derived from bone marrow in a phase IIa randomized clinical trial in the Netherlands. There were twentyone patients with refractory perianal fertilizing CD included; five were given a single shot of 1 × 107 MSCs, five were given 3 × 107 MSCs, five were given 9 × 107 MSCs, and six were given placebo. These injections were placed around the internal openings of fistula walls. Fistula healing was determined to be cessation of drainage and absence of fluid collections > 2 cm on MRI, and was observed in refractory perianal CD. This trial, dubbed Stem Cells on Matrix Plugs (STOMP), delivered concentrated, adiposederived MSC attached to a bioabsorbable ma trix to 12 patients. By three months, 9 of 12 patients (75%) achieved complete healing through clinical and radiographic determination; by six months, 10 of 12 of patients (83%) achieved this. There were no serious adverse events due to MSC therapy nor plug placement, and the study authors found these matrix plugs to be safe and effective for refractory perianal CD [14] .
AUTOLOGOUS BONE MARROW STEM CELL STUDIES
There is much less data available regarding autologous bone marrow MSC treatment, compared to adipose derived MSC treatment, in CD. A study led by Ci ccocioppo utilized nine subjects with actively draining complex perianal fistulas who received intrafistular injections of bone marrowderived MSC once monthly until healing was achieved or until they were no longer accessible. In all subjects, MSC expansion was successful. The fistulas were wholly closed in six of nine (67%) subjects at two months, with continued results at twelve months; in the other three cases incomplete closure was achieved [15] . Dailey FE et al . Stem cell therapy for perianal CD seven of 15 (47%) of those administered MSCs and two of 6 (33%) of those given placebo. These encouraging results were found not only at the study's primary endpoint, week twelve, but also endured through week twentyfour. Amongst the range of dosages of MSCs given, the best effects were observed in those given 3 × 107. Notably, none of the treatment regimens were associated with an increase in adverse events ( Table  1 ) [17] .
ALLOGENEIC ADIPOSE STEM CELL STUDIES

CONCLUSION
Perianal CD is quite challenging for both patients and providers with delayed and difficult healing, des pite current standard therapy including antibiotics, immunomodulators, antiTNF treatment, and surgical repair. Need for novel treatment options to improve outcomes in these patients is obvious. Here, the promising results of recent and ongoing studies utilizing stem cell therapyeither allogeneic or autologousfor treatment of this patient population are presented. Given this data, the authors conclude that future randomized doubleblind, placebocontrolled multicenter studies on the efficacy and safety of stem cell therapy for perianal disease in CD are warranted.
